PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

Gerald G Krueger Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

07/2008	Genetics of psoriasis and psoriatic arthritis: update and future direction.
05/2008	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
01/2008	A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
02/2007	A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
03/2006	Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
12/2005	An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
11/2005	Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
12/2004	Alefacept: a novel biologic in the treatment of psoriasis.
10/2004	Current concepts and review of alefacept in the treatment of psoriasis.
01/2004	Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in psoriasis treatment.
12/2003	A randomized trial of etanercept as monotherapy for psoriasis.
08/2003	Development and use of alefacept to treat psoriasis.
05/2003	Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
04/2003	Efficacy of acitretin and commercial tanning bed therapy for psoriasis.
12/2002	A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
05/2002	A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.
04/2002	Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis.

Articles by Research Topic

Disease

17	Psoriasis (Pustulosis Palmaris et Plantaris) 07/2008 - 04/2002
2	Psoriatic Arthritis 07/2008 - 11/2006
1	Atopic Dermatitis (Atopic Eczema) 02/2007
1	Seborrheic Keratosis 04/2004
1	Epidermolysis Bullosa Dystrophica (Dystrophic Epidermolysis Bullosa) 11/2003

Drug/Important Bio-Agent (IBA)

7	alefacept (Amevive)FDA Link 01/2008 - 04/2002
4	TNFR-Fc fusion protein (etanercept)FDA Link 03/2006 - 12/2003
2	Interleukin-12 (IL 12)IBA 05/2008 - 02/2007
2	tazarotene (Tazorac)FDA Link 04/2004 - 05/2003
1	Direction compoundIBA 07/2008
1	Tacrolimus (Prograf)FDA Link 02/2007
1	infliximab (Remicade)FDA Link 11/2006
1	imiquimod (Aldara)FDA Link 04/2004
1	calcipotriene (calcipotriol)FDA LinkGeneric 04/2004
1	efalizumab FDA Link 01/2004
1	Collagen Type VIIIBA 11/2003
1	Acitretin FDA Link 04/2003
1	Clobetasol (Clobetasol Propionate)FDA LinkGeneric 05/2002

Therapy/Procedure

1	Cryosurgery 04/2004